BBT594 Inhibitor

BBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,treatment,of cancer.

Zhang Q, Shi C, Han L, et al. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia[J]. Oncotarget, 2018, 9(8).
Zhang Q, Shi C, Han L, et al. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia[J]. Oncotarget, 2018, 9(8).
Morandi A, Martin L A, Gao Q, et al. GDNF-RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors[J]. Cancer Research, 2013, 73(12):3783-3795.
Morandi A, Martin L A, Gao Q, et al. GDNF-RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors[J]. Cancer Research, 2013, 73(12):3783-3795.
Andreucci E, et al. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget. 2016 Sep 2. doi: 10.18632/oncotarget.11826. [Epub ahead of print]

Small volumes of BBT594, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5758316 is an inhibitor targeting BBT594.